The global cardiovascular biomarker testing market accounted for US$ 6.9 Bn in 2020 with a considerable CAGR of 8.5% during the forecast period of 2021 to 2028.
|Market||Cardiovascular Biomarker Testing Market|
|Analysis Period||2017 - 2028|
|Forecast Data||2021 - 2028|
|Segments Covered||By Biomarker Type, By Disease Type, By End-User, and By Geography|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||
Becton, Dickinson and Company, Abbott Laboratories, Bio-Rad Laboratories, Inc., BioMérieux, F. Hoffmann-La Roche AG, Danaher Corporation, Randox Laboratories, Thermo Fisher Scientific. And Siemens Healthineers, among others
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
10 hrs of free customization and expert consultation
When the heart is damaged or strained, molecules called cardiac biomarkers are released into the bloodstream. Measurements of the biomarkers are useful for determining number of cardiovascular and heart related disorders such as cardiac ischemia, acute coronary syndrome, myocardial infarction, etc. Cardiac biomarker tests can also be used to evaluate a person's risk of developing these illnesses, as well as to observe and manage patients who have been already diagnosed with cardiac disorders. Heart biomarker tests are ordered to help diagnose and assess the severity of cardiac ischemia and acute coronary syndrome. Presence of one or more markers in the blood can help identify the disease and severity of the same, allowing a quick and precise diagnosis and treatment.
Growing burden of Cardiovascular Diseases (CVDs) around the world
CVDs have a high prevalence rate worldwide and account for most number of deaths globally, with more than 17.9 million lives succumbing to CVD every year. Cerebrovascular diseases, coronary heart disorders, rheumatic heart disorders and other heart and blood vessel problems are terms of cardiovascular diseases. Strokes and heart attacks claim 4 out 5 deaths due to CVD, with one-third deaths occurring before the age of 70. According to a report published in the Journal of the American College of Cardiology that studied the enormity of cardiovascular diseases and tendency over the last 30 years globally, the number of people dying from CVD is steadily rising, accounting for one-third of all deaths globally in 2019. The results emphasize the urgent need of cost-effective preventive measures aimed at lowering CVD risk by the countries. The findings suggest that the CVD prevalence surge twice-fold between the periods of 1990 to 2019 from 271 million to 523 million respectively, while the mortality rate too increased gradually during the same period from 12.1 million to 18.6 million. Ischemic heart disease and stroke accounted for the majority of CVD deaths worldwide in 2019, a trend that has been increasing steadily since 1990. The most common risk factors identified are sedentary lifestyle, unhealthy and untimely diet, limited physical activity and increased consumption of alcohol and tobacco. These factors have direct or indirect effect on the person’s blood pressure, lipids, and blood glucose level resulting in overweight and obesity which ultimately leads to more severe and prolonged complications such as heart diseases, strokes and heart failures among others.
The COVID-19 pandemic is an once-in-a-lifetime global public health challenge that is expected to benefit the cardiovascular diagnostic testing market. Aside from the lungs, this infectious disease has serious consequences for the cardiovascular system, which contributes to the market's positive impact. COVID-19 appears to promote the development of cardiovascular disorders like myocardial infarction, arrhythmias, and acute coronary syndrome. Furthermore, patients with pre-existing co-morbidities and heart problems if happen to contract COVID-19 infection are more likely to have a heart attack or develop congestive heart failure. Furthermore, coronavirus infection is said to affect the endothelial lining of arteries and vein resulting in the inflammation of blood vessels and in some cases even damage of cells and clot formations. This results in the improper blood flow to the heart and other parts of the body leading to severe damage to the vital organs of the body. Thus, the pandemic of COVID-19 has emphasized the importance of dependable diagnostic tests and the rapid progress of novel assays.
The cardiovascular biomarker testing market is segmented on the biomarker type, disease type and end-user type. Based on the biomarker type, the market is segmented as kinase, troponins, myoglobin, ischemia modified albumin, high-sensitivity c-reactive protein (hscrp), others. The troponins test segment held the largest share in the market and expected to continue to its dominance during the forecast period. Troponin tests are used to detect heart injury by measuring the level of cardiac-specific troponin in the blood. Troponin is released into the bloodstream when heart muscle cells are damaged. Troponin tests are used to determine whether or not a person has had a heart attack. High level of accuracy and precision of this test helps it dominate the biomarker type segment. In terms of disease type, the market is segmented as congestive heart failure, acute coronary syndrome, myocardial infarction, atherosclerosis, ischemia. Myocardial infarction accounted for the maximum share in the market in terms of disease type. High incidence of the disease is the major reason for the growth of the segment.
North America accounts for the dominant share in the market in 2020
North America accounted for the maximum share in the global cardiovascular biomarker testing market driven by developed healthcare scenario in the US. The US holds the lion’s share in the North America market owing to high prevalence of cardiovascular diseases in the country. In US, heart disease is the most common cause of death in people of all ethnicity. The Centers for Disease Control and Prevention (CDC) estimates that 1 person dies every 36 seconds due to CVD in the US and approximately 0.65 million people succumb to heart disease each year. Apart from high prevalence, the country boasts a sophisticated healthcare infrastructure and high awareness towards CVD and other diseases, making CVD biomarkers necessary tests in the routine check-ups.
The prominent players operating in the global cardiovascular biomarker testing market include Becton, Dickinson and Company, Abbott Laboratories, Bio-Rad Laboratories, Inc., BioMérieux, F. Hoffmann-La Roche AG, Danaher Corporation, Randox Laboratories, Thermo Fisher Scientific. And Siemens Healthineers, among others
Market By Biomarker Type
Market By Disease Type
Market By End-User
Market By Geography
The estimated value of Global Cardiovascular Biomarker Testing Market was accounted to be US$ 16.2 Bn by 2028
The projected CAGR of Cardiovascular Biomarker Testing during the analysis period of 2021 to 2028 is 8.5%
Asia pacific region exhibited fastest growing CAGR for Cardiovascular Biomarker Testing during the analysis period of 2021 to 2028
Growing prevalence of cardiovascular diseases, unhealthy lifestyle and positive impact of Covid-19 market are driving the market